Cullen/Frost Bankers, Inc. Sarepta Therapeutics, Inc. Transaction History

Cullen/Frost Bankers, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$113.33 - $163.85 $1,813 - $2,621	16 New	16 $2,000
Q2 2023 Aug 04, 2023	SELL	$106.4 - $157.19 $10,640 - $15,719	-100 Reduced 25.0%	300 $34,000
Q3 2022 Nov 07, 2022	BUY	$75.71 - $119.24 $30,283 - $47,696	400 New	400 $44,000
Q4 2020 Feb 08, 2021	SELL	$125.56 - $178.74 $627 - $893	-5 Closed	0 $0
Q3 2020 Nov 05, 2020	BUY	$127.12 - $172.34 $635 - $861	5 New	5 $1,000

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.